Exentis Group AG, provider of a 3D technology platform that enables large-scale industrial production, has delivered a latest-generation Exentis Pharma production system to a leading pharmaceutical manufacturer (CDMO) in Italy.
Exentis Pharma production system of the latest generation being installed in the newly equipped clean room 3D production space of an Italian customer.
The proprietary Exentis 3D technology platform makes it possible for the first time to additively produce tablets with a freely adjustable release profile of active pharmaceutical ingredients in the human body. Thus, Exentis technology creates a completely new market segment.
Dr Gereon Heinemann, Chief Executive Officer of Exentis Group AG: “With the delivery of one of our Exentis Pharma production systems of the latest generation to Italy, our innovative clean room production technology is now also present on this market. The delivered 3D system is capable of additively producing up to 10 million tablets per year. Our modularly expandable production systems have an annual production capacity of currently up to 200 million tablets, with up to three active pharmaceutical ingredients per tablet, and with convincing benefits for patients. This makes Exentis a global pioneer in technology platforms for the production of 3D-printed pharmaceutical products.”
In addition to the pharma market, Exentis will use its innovative production technology to tap into further attractive growth markets in the future in which products are also manufactured using clean room technology. These include markets such as pet medicine and nutritional supplements
Subscribe to our Newsletter
3DPResso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
